These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17094994)

  • 21. Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions.
    Scicchitano F; Constanti A; Citraro R; De Sarro G; Russo E
    Curr Drug Targets; 2015; 16(7):747-56. PubMed ID: 25901524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HMG-CoA reductase inhibitors and coenzyme Q10.
    Nawarskas JJ
    Cardiol Rev; 2005; 13(2):76-9. PubMed ID: 15705257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies.
    Taha DA; De Moor CH; Barrett DA; Gershkovich P
    Transl Res; 2014 Aug; 164(2):85-109. PubMed ID: 24530275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statin safety and drug interactions: clinical implications.
    Bottorff MB
    Am J Cardiol; 2006 Apr; 97(8A):27C-31C. PubMed ID: 16581325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins, cardiovascular disease, and drug safety.
    Gotto AM
    Am J Cardiol; 2006 Apr; 97(8A):3C-5C. PubMed ID: 16581326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of statin-intolerant patient.
    Arca M; Pigna G; Favoccia C
    Panminerva Med; 2012 Jun; 54(2):105-18. PubMed ID: 22525565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins and cognitive side effects: what cardiologists need to know.
    Rojas-Fernandez C; Hudani Z; Bittner V
    Cardiol Clin; 2015 May; 33(2):245-56. PubMed ID: 25939297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
    Bangalore S; Fayyad R; Hovingh GK; Laskey R; Vogt L; DeMicco DA; Waters DD;
    Am J Cardiol; 2014 Jun; 113(12):2018-20. PubMed ID: 24793673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins in hemorrhagic stroke.
    Flaster M; Morales-Vidal S; Schneck MJ; Biller J
    Expert Rev Neurother; 2011 Aug; 11(8):1141-9. PubMed ID: 21797655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statin-induced myopathy: the two faces of Janus.
    Arora R; Liebo M; Maldonado F
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):105-12. PubMed ID: 16891287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of statins in patients with liver disease.
    Kalaitzakis E; Björnsson ES
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):15-24. PubMed ID: 24632765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New treatment option for decreasing blood cholesterol level--clinical significance of inhibition of both, cholesterol absorption and synthesis].
    Paragh G; Márk L; Czine Z
    Orv Hetil; 2004 Apr; 145(15):805-11. PubMed ID: 15188635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The controversy of a wider statin utilization: why?
    Mansi I; Mortensen E
    Expert Opin Drug Saf; 2013 May; 12(3):327-37. PubMed ID: 23488561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The acute (cerebro)vascular effects of statins.
    Prinz V; Endres M
    Anesth Analg; 2009 Aug; 109(2):572-84. PubMed ID: 19608834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
    Olyaei A; Greer E; Delos Santos R; Rueda J
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of perioperative statin therapy for noncardiac surgery.
    Skrlin S; Hou V
    Semin Cardiothorac Vasc Anesth; 2010 Dec; 14(4):283-90. PubMed ID: 21041202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Statin-induced adverse effects -- facts and genes].
    Harangi M; Zsíros N; Juhász L; Paragh G
    Orv Hetil; 2013 Jan; 154(3):83-92. PubMed ID: 23315223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins: Adverse reactions, oxidative stress and metabolic interactions.
    Liu A; Wu Q; Guo J; Ares I; Rodríguez JL; Martínez-Larrañaga MR; Yuan Z; Anadón A; Wang X; Martínez MA
    Pharmacol Ther; 2019 Mar; 195():54-84. PubMed ID: 30321555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.